These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1. Grigorescu-Sido P, Drugan C, Alkhzouz C, Zimmermann A, Coldea C, Denes C, Grigorescu MD, Cret V, Bucerzan S. Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881 [Abstract] [Full Text] [Related]
3. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease]. Pérez-Calvo JI, Giraldo P, Giralt M. Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260 [Abstract] [Full Text] [Related]
4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease]. Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM. Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655 [Abstract] [Full Text] [Related]
5. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Pastores GM, Sibille AR, Grabowski GA. Blood; 1993 Jul 15; 82(2):408-16. PubMed ID: 8392397 [Abstract] [Full Text] [Related]
7. Enzyme replacement and substrate reduction therapy for Gaucher disease. Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM. Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601 [Abstract] [Full Text] [Related]
8. Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data. Raskovalova T, Deegan PB, Yang R, Pavlova E, Stirnemann J, Labarère J, Zimran A, Mistry PK, Berger M. Syst Rev; 2017 Apr 20; 6(1):87. PubMed ID: 28427477 [Abstract] [Full Text] [Related]
9. Velaglucerase alfa for the management of type 1 Gaucher disease. Morris JL. Clin Ther; 2012 Feb 20; 34(2):259-71. PubMed ID: 22264444 [Abstract] [Full Text] [Related]
10. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, Zimran A, Foster MC, Gaemers SJM, Peterschmitt MJ. Am J Hematol; 2019 Jan 20; 94(1):29-38. PubMed ID: 30264864 [Abstract] [Full Text] [Related]
11. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Czartoryska B, Tylki-Szymańska A, Górska D. Clin Biochem; 1998 Jul 20; 31(5):417-20. PubMed ID: 9721443 [Abstract] [Full Text] [Related]
12. Enzyme replacement therapy for Gaucher disease in Australia. Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M. Intern Med J; 2005 Mar 20; 35(3):156-61. PubMed ID: 15737135 [Abstract] [Full Text] [Related]
13. Effect of treatment on biclonal gammopathy associated with Gaucher disease. Decaux O, Ruelland A, Grosbois B. J Inherit Metab Dis; 2007 Oct 20; 30(5):824. PubMed ID: 17879146 [Abstract] [Full Text] [Related]
14. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations. Piran S, Roberts A, Patterson MA, Amato D. Blood Cells Mol Dis; 2009 Oct 20; 43(3):289-93. PubMed ID: 19793665 [Abstract] [Full Text] [Related]
15. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A. Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749 [Abstract] [Full Text] [Related]
16. Therapeutic goals in Gaucher disease. Mistry P, Germain DP. Rev Med Interne; 2006 Mar 01; 27 Suppl 1():S30-8. PubMed ID: 16644400 [Abstract] [Full Text] [Related]